Date
2021-12-14Journal
BMJPublisher
BMJ Publishing GroupType
Article
Metadata
Show full item recordDescription
The authors discuss how the end of the COVID-19 pandemic will be defined and whether or not real-time metrics from data dashboards are delaying the public's "sense of closure".See also Authors’ reply to Chiolero, Bannon, and Dickinson at https://doi.org/10.1136/bmj.o170
Identifier to cite or link to this item
http://hdl.handle.net/10713/17394ae974a485f413a2113503eed53cd6c53
10.1055/s-0043-113690
Scopus Count
Collections
Related articles
- Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
- Authors: Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M, BEMED Study Group
- Issue date: 2016 Jan 21
- Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.
- Authors: Nauta JJ
- Issue date: 2014 May
- [Trimetazidine versus betahistine in Ménière's disease. A double blind method].
- Authors: Martini A, De Domenico F
- Issue date: 1990
- [Treatment of Meniere disease with betahistine dimesilate (Aequamen)--double-blind study versus placebo (crossover)].
- Authors: Meyer ED
- Issue date: 1985 May
- Betahistine Prescribing Practices in England: An Analysis of Prescribing and National Spending Pre- and Post-BEMED Trial.
- Authors: Sutton L, Ghedia R, Harcourt J
- Issue date: 2023 Jul 1